Endocrine-responsive breast cancer and strategies for combating resistance
- 1 February 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 2 (2), 101-112
- https://doi.org/10.1038/nrc721
Abstract
Deaths from breast cancer have fallen markedly over the past decade due, in part, to the use of endocrine agents that reduce the levels of circulating oestrogens or compete with oestrogen for binding to its receptor. However, many breast tumours either fail to respond or become resistant to endocrine therapies. By understanding the mechanisms that underlie this resistance, we might be able to develop strategies for overcoming or bypassing it.Keywords
This publication has 99 references indexed in Scilit:
- The language of covalent histone modificationsNature, 2000
- Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 SitesScience, 1997
- The Transcriptional Coactivators p300 and CBP Are Histone AcetyltransferasesCell, 1996
- ERβ: Identification and characterization of a novel human estrogen receptorFEBS Letters, 1996
- Cloning of a novel receptor expressed in rat prostate and ovary.Proceedings of the National Academy of Sciences of the United States of America, 1996
- A transcriptional co-repressor that interacts with nuclear hormone receptorsNature, 1995
- Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-ANature, 1986
- A two-step mechanism for the interaction of estradiol with rat uterus.Proceedings of the National Academy of Sciences of the United States of America, 1968
- A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization.Proceedings of the National Academy of Sciences of the United States of America, 1966
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896